WO2017062694A1 - Compositions and methods of treating skin fibrotic disorders - Google Patents

Compositions and methods of treating skin fibrotic disorders Download PDF

Info

Publication number
WO2017062694A1
WO2017062694A1 PCT/US2016/055865 US2016055865W WO2017062694A1 WO 2017062694 A1 WO2017062694 A1 WO 2017062694A1 US 2016055865 W US2016055865 W US 2016055865W WO 2017062694 A1 WO2017062694 A1 WO 2017062694A1
Authority
WO
WIPO (PCT)
Prior art keywords
dermal
phase modulator
wound
soluble guanylate
wound healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/055865
Other languages
French (fr)
Inventor
Diane Tang-Liu
Tiffany Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US15/767,137 priority Critical patent/US10736885B2/en
Priority to CA3001489A priority patent/CA3001489C/en
Priority to EP16854374.2A priority patent/EP3359258A4/en
Priority to AU2016335675A priority patent/AU2016335675B2/en
Priority to KR1020187012515A priority patent/KR102317700B1/en
Priority to JP2018538059A priority patent/JP7153331B2/en
Priority to CN201680071285.5A priority patent/CN108367165B/en
Publication of WO2017062694A1 publication Critical patent/WO2017062694A1/en
Anticipated expiration legal-status Critical
Priority to US16/920,278 priority patent/US20200330446A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • This invention relates to compositions and methods for preventing or treating formation of fibrotic lesions, including skin scars such as keloids and hypertrophic scars.
  • Dermal wound healing involves several phases: hemostasis, inflammation, proliferation, and tissue maturation.
  • the overall process is induced and regulated by a complex array of factors, such as growth factors and cytokines.
  • the initial hemostasis controls the release of a variety of growth factors and/or cytokines from activated platelets to promote blood clotting.
  • the hemostasis phase is followed by the inflammation phase.
  • the inflammation phase induces vasodilation and results in an influx of lymphocytes and macrophages.
  • Macrophages will release growth factors, such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor- ⁇ (TGF- ⁇ ), vascular endothelial growth factor (VEGF), interleukin-1 (IL-1), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) that stimulate fibroblasts cells to promote the proliferation phase.
  • growth factors such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor- ⁇ (TGF- ⁇ ), vascular endothelial growth factor (VEGF), interleukin-1 (IL-1), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) that stimulate fibroblasts cells to promote the proliferation phase.
  • any improper action of these factors in any phase may result in improper wound healing.
  • excessive fibrosis may lead to undesirable scar formation.
  • a therapy may need to modulate more than one phase and target for a positive wound repair outcome.
  • Embodiments of the present invention relate to compositions and methods for preventing and/or modulating the formation of dermal fibrotic disorders.
  • Embodiments of the invention are based on therapeutic utilities of compounds possessing certain spectrum of pharmacologic effects to modulate exuberant activities in various phases of wound healing, thereby preventing and/or alleviating aberrant fibrotic tissue formations (e.g., scar formations).
  • compounds of the invention include agents that can interfere with multiple phases (multiple targets) of wound healing processes.
  • multi-phase modulators or “multi-target modulators.”
  • the “multi-phase modulators” or “multi-target modulators” may include multikinase inhibitors that can inhibit multiple kinases, as well as soluble guanylate cyclase (SGC) stimulators that can stimulate the activities of soluble guanylate cyclase.
  • SGC soluble guanylate cyclase
  • embodiments of the invention relate to methods for preventing and/or modulating formation of a dermal fibrotic disorder.
  • a method in accordance with embodiments of the invention includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof.
  • the subject may be a mammal, particularly a human.
  • a multi-phase modulator may be a multiple-kinase ("multikinase”) inhibitor or a soluble guanylate cyclase (SGC) stimulator (e.g., riociguat).
  • multikinase inhibitor refers to a compound that can inhibit multiple kinases, particularly multiple receptor tyrosine kinases.
  • a soluble guanylate cyclase (SGC) stimulator can stimulate the activity of an SGC, leading to the formation of cyclic GMP (cGMP), which is a second messenger in various signal transduction pathways.
  • cGMP cyclic GMP
  • a multikinase inhibitor may include axitinib, nintedanib, sorafenib, sunitinib or lenvatinib, which can inhibit receptor tyrosine kinases, such as VEGFR receptors (VEGFR-1, VEGFR- 2, and/or VEGFR-3) and PDGF receptors (PDGFR1 and/or PDGFR2).
  • receptor tyrosine kinases such as VEGFR receptors (VEGFR-1, VEGFR- 2, and/or VEGFR-3) and PDGF receptors (PDGFR1 and/or PDGFR2).
  • VEGFR receptors VEGFR-1, VEGFR- 2, and/or VEGFR-3
  • PDGF receptors PDGF receptors
  • compounds of the invention e.g., axitinib, nintedanib, sorafenib, sunitinib, and lenvatinib
  • FGFR fibroblast growth factor receptors
  • the multikinase inhibitors may include, but are not limited to, axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and their stereoisomer, tautomer, prodrug, free base, analogs, metabolites, pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
  • These compounds have anti-multikinase activities, such as anti- VEGFR, anti-PDGFR, and/or anti-FGFR activities.
  • these multikinase inhibitors can inhibit exuberant tissue fibrosis or scar formation. They are effective in remedying undesired scar formation, presumably due to their abilities to inhibit multiple kinases, such as receptor tyrosine kinases that mediate signal transductions in the various phases of wound healing, thereby modulating the wound healing processes at multiple phases.
  • multiple kinases such as receptor tyrosine kinases that mediate signal transductions in the various phases of wound healing, thereby modulating the wound healing processes at multiple phases.
  • a "pharmaceutically acceptable salt” refer to a compound that has been modified by adding an acid or base to make a salt thereof, wherein the compound may be a parent compound, or a prodrug, a derivative, a metabolite, or an analog of the parent compound.
  • the multikinase inhibitor is axitinib.
  • Axitinib is a tyrosine kinase inhibitor of VEGFR- 1, VEGFR-2 and VEGFR-3.
  • Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival.
  • Axitinib also inhibits closely related receptor tyrosine kinases (RTKs), such as PDFGR-1, PDGFR-2, and KIT.
  • RTKs receptor tyrosine kinases
  • the multikinase inhibitor is nintedanib. Nintedanib is tyrosine kinase inhibitor of various receptors, such as VEGFR, FGFR, PDGFR-a and PDGFR- ⁇ , and FGF. [0017] In accordance with some embodiments of the invention, the multikinase inhibitor is sorafenib. Sorafenib is a tyrosine kinase inhibitor of several receptors, such as VEGFR-2, VEGFR-3 and PDGFR2
  • the multikinase inhibitor is sunitinib.
  • Sunitinib is tyrosine kinase inhibitor of VEGFR and PDGFR.
  • the multikinase inhibitor is lenvatinib.
  • Lenvatinib is a tyrosine kinase receptor inhibitor of various receptors, such as VEGFR- 1, VEGFR-2, VEGFR-3, FGFR-1, FGFR-2, FGFR-3, FGFR-4, and PDGFR-a.
  • the multi-phase modulator is an SGC stimulator, such as riociguat.
  • SGC stimulator such as riociguat.
  • Riociguat a soluble guanylate cyclase stimulator, may have effects on proliferation, fibrosis and inflammation in wound healing.
  • an agent for controlling exuberant activities in various phases of wound healing may be used with other types of agents that can interfere with one or more phases involved in wound healing.
  • These other agents may include anti-angiogenic agents, anti-inflammatory agents, or anti- vascular permeability agents.
  • Preferred anti-angiogenic agents include, but are not limited to, tyrosine kinase inhibitors, in particular, those targeting multiple receptors, such as those described in further detail herein: angiostatic cortisenes; matrix metalloprotease inhibitors; integrin inhibitors; PDGF antagonists; anti-proliferatives; hypoxia inducible factor-I inhibitors; fibroblast growth factor inhibitors; epidermal growth factor inhibitors; tissue inhibitor of metalloproteinases inhibitors; insulin-like growth factor inhibitors; tumor necrosis factor inhibitors; antisense oligonucleotides; anti-VEGF antibody, VEGF trap, anti-VEGF and/or anti-PDGF compounds, and their stereoisomer, tautomer, prodrug, free base, analogs, metabolites, pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
  • the dermal fibrotic disorders include but not limited to acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, Peyronie's disease, dupuytren's contracture, or adhesive capsulitis.
  • compounds/molecules of the present invention may be administered by oral, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingual, intramuscular, intradermal, subcutaneous, topical, intranasal, intraperitoneal, intrathoracic, intralesional, paralesional, intravenous, epidural, intrathecal, or intracerebroventricular routes, or by injection into the tissue and/or joints.
  • FIG. 1 shows TGF- ⁇ mRNA expression levels in wound sites treated with compounds of the invention relative to those in an untreated unwounded site on the dorsum of pigs.
  • FIG. 2 shows images of pig dermal tissues from histologic slides after hematoxylin and eosin staining. There was a decrease in neovascularization and fibrosis in drug treatment groups as compared to the untreated wound control.
  • Panel (A) unwounded normal skin.
  • Panel (B) untreated wound tissue, showing more neovascularization and fibrosis.
  • Panel (C) axitinib treated wound, showing neovascularization and reduced fibrosis.
  • FIG. 3 shows results of nintedanib (labeled as AIV002) treatment of rabbit ear hypertrophic scar. Nintedanib treatment decreased neovascularization and dermal fibrosis.
  • Panel (A) shows H&E staining (left: untreated; right: treated wound), wherein the untreated site has substantial neovascularization (left), relative to the treated site (right).
  • Panel (B) shows Mason' s Trichrome staining (left: untreated; right treated wound).
  • Embodiments of the present invention relate to compositions (multi-phase modulators) and methods for preventing and/or modulating the formation of dermal fibrotic disorders.
  • Dermal wound healing involves several phases: hemostasis, inflammation, proliferation, and tissue maturation. The overall process is induced and regulated by a complex array of factors, such as growth factors and cytokines. Effective approaches to the control of exuberant activities in would healing likely require controls and modulations in multiple phases.
  • Factors involved in wound healing exert their functions by binding to their respective receptors to activate various signaling pathways. These receptors include tyrosine kinases.
  • receptor tyrosine kinase inhibitors can be used to regulate the exuberant wound healing processes.
  • Embodiments of the invention are based on therapeutic utilities of compounds that possess a certain spectrum of pharmacologic effects to modulate exuberant activities in various phases of wound healing, thereby preventing and/or alleviating aberrant fibrotic tissue formations (e.g., scar formations).
  • compounds of the invention include multikinase inhibitors that can inhibit multiple kinases, thereby interfering with multiple kinase-mediated signaling pathways.
  • multikinase inhibitors that can inhibit multiple kinases, thereby interfering with multiple kinase-mediated signaling pathways.
  • Compounds of the invention may include axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, and regorafenib, which can potently inhibit receptor tyrosine kinases, such as VEGFR receptors (VEGFR-l, VEGFR-2, and/or VEGFR-3) and/or PDGF receptors (PDGFRl and/or PDGFR2).
  • VEGFR receptors VEGFR receptors
  • VEGFR-2 VEGFR-2, and/or VEGFR-2
  • VEGFR-2 PDGF receptors
  • PDGFRl and/or PDGFR2 PDGF receptors
  • these compounds also have different extents of inhibitory potencies against fibroblast growth factor receptors (FGFR). Having the abilities to inhibit multiple receptor tyrosine kinases (e.g., VEGFR, PDGFR, and/or FGFR), these compounds
  • soluble guanylate cyclase (SGC) stimulators may also be used in embodiments of the invention. SGC stimulators may also interfere with multiple phases of wound healing.
  • a compound of the invention may be an SGC stimulator, such as riociguat.
  • the term "dermal fibrotic disorder” refers to exuberant activities in various phases of wound healing that would result in aberrant fibrotic tissue formations (e.g., scar formations).
  • a "therapeutic effective amount” is an amount that would achieve the desired therapeutic effects. A therapeutic effective amount would depend on the patient conditions, routes of administration, administration regimes etc. One skilled in the art would be able to determine a therapeutic effective amount without inventive efforts.
  • Porcine skin resembles human skin in many aspects. Both species have a relatively thick epidermis, distinct rete pegs, dermal papillae, and dense elastic fibers in the dermis. Furthermore, unlike rodents and rabbits, porcine skin is adherent to the subcutaneous structures, similar to human skin. Because of these anatomical similarities and other parallelisms in wound healing, porcine models have emerged as important foundations for the study of pathophysiology and potential treatment paradigms for abnormal wound healing. It has also been observed in porcine full- thickness wound healing in Yucatan Minipigs that the spatial and temporal expressions of TGF-B1, PDGF and VEGF were similar to the patterns for the growth factors described above. Therefore, the full-thickness excision models in Yucatan minipigs are the models for human wound healing studies.
  • a dose (e.g., 1%) of axitinib, nintedanib, riociguat, sorafenib, sunitinib, and/or lenvatinib was administered into the dermal tissue at or around the wound sites, once every two weeks on two occasions.
  • One wound site was left untreated as the control for each pig.
  • the dosages, administration methods, treatment regimen, and the administration sites may be varied to achieve similar results.
  • total mRNA was isolated from skin biopsies of the treated wound sites and the untreated unwounded sites of the pigs.
  • the mRNA samples were used to prepare cDNA and analyzed via qRT-PCR.
  • the TGF- ⁇ expression levels were assessed using beta actin as a reference gene.
  • Transfomiing-growth-factor ( ⁇ )- ⁇ expression results in increased production of extracellular matrix (ECM) components, as well as mesenchymal cell proliferation, migration, and accumulation. Therefore, TGF- ⁇ has been found to induce fibrosis associated with chronic phases of inflammatory diseases. As shown in FIG. 1, compounds of the invention significantly reduced the expression levels of TGF- ⁇ , suggesting that compounds of the invention can be used to control undesired fibrosis.
  • ECM extracellular matrix
  • axitinib and nintedanib noticeably reduced neovascularization with a corresponding reduced dermal fibroplasia, as assessed by histopathologic examinations of the treated wounds relative to the untreated wound (Table. 1).
  • FIG. 2 shows exemplary hematoxylin and eosin stainings of pig dermal tissues from treated and untreated wound sites.
  • Panel (A) show a staining from an unwounded skin as a control.
  • Panel (B) shows a staining of a sample from a wounded site without treatment with any compound of the invention. It is evident that the wounded tissue has substantial neovascularization and fibrosis.
  • Panel (C) shows a staining of a sample from a wounded site treated with axitinib. Axitinib treatment results in significantly reduced neovascularization and reduced fibrosis, as compared with the untreated wound (see Panel (B)).
  • a dose (e.g., 1%) of axitinib, nintedanib, riociguat, sorafenib, sunitinib, and/or lenvatinib was administered into the dermal tissue, once every two weeks on two occasions.
  • the specific doses, treatment methods and schedules are for illustration only. One skilled in the art would appreciate that variations and modifications are possible to achieve similar results.
  • Histologic slides for hematoxylin and eosin stainings were prepared from the wound sites. Tissues were evaluated qualitatively for inflammation, neovascularization, granulation tissue, degrees of re-epithelialization, and degrees of scarring (avascular collagen).
  • the wounds treated with nintedanib had much less neovascularization and less scar tissues.
  • the mean TGFbl mRNA level was lower after intradermal treatment with nintedanib.
  • FIG. 3 shows results of nintedanib (labeled as AIV002) treatment of rabbit ear hypertrophic scar. Nintedanib treatment decreased neovascularization and dermal fibrosis.
  • Panel (A) shows H&E staining (left: untreated; right: treated wound), wherein the untreated site has substantial neovascularization (left), relative to the treated site (right).
  • Panel (B) shows Mason' s Trichrome staining (left: untreated; right treated wound).
  • nintedanib In addition to nintedanib, other compounds of the invention also have similar effects. For example, As compared with the untreated wound and the vehicle-treated wound, the wounds treated with axitinib had less neovascularization, less fibrosis, and less scar tissues. As compared with the vehicle-treated wound, the mean TGFbl mRNA level was lower after intradermal treatment with axitinib.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, Peyronie's disease, dupuytren's contracture, or adhesive capsulitis

Description

COMPOSITIONS AND METHODS OF TREATING SKIN FIBROTIC
DISORDERS
CROSS REFERECE TO RELATED APPLICATIONS
[0001] This claims the benefits of U.S. Provisional Patent Application No. 62/238,309, filed on October 7, 2015, the disclosure of which is incorporated by reference in its entirety.
TECHNICAL FIELD
[0002] This invention relates to compositions and methods for preventing or treating formation of fibrotic lesions, including skin scars such as keloids and hypertrophic scars.
BACKGROUND
[0003] Dermal wound healing involves several phases: hemostasis, inflammation, proliferation, and tissue maturation. The overall process is induced and regulated by a complex array of factors, such as growth factors and cytokines.
[0004] The initial hemostasis controls the release of a variety of growth factors and/or cytokines from activated platelets to promote blood clotting. The hemostasis phase is followed by the inflammation phase.
[0005] The inflammation phase induces vasodilation and results in an influx of lymphocytes and macrophages. Macrophages will release growth factors, such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), interleukin-1 (IL-1), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) that stimulate fibroblasts cells to promote the proliferation phase.
[0006] As the proliferative phase progresses, these growth factors stimulate angiogenesis and fibroplasias to rebuild blood flow to tissues after injury. Finally, the tissues mature to complete the wound healing processes. The tissue maturation phase also requires growth factors to control cell differentiation.
[0007] Because the wound healing processes involve multiple phases that require different factors at different times, any improper action of these factors in any phase may result in improper wound healing. For example, excessive fibrosis may lead to undesirable scar formation.
[0008] Given these multiple factors and their spatial and temporal interactions, identifying an appropriate drug treatment strategy is challenging. For effective controls of dermal wound healing, a therapy may need to modulate more than one phase and target for a positive wound repair outcome.
SUMMARY OF THE INVENTION
[0009] Embodiments of the present invention relate to compositions and methods for preventing and/or modulating the formation of dermal fibrotic disorders. Embodiments of the invention are based on therapeutic utilities of compounds possessing certain spectrum of pharmacologic effects to modulate exuberant activities in various phases of wound healing, thereby preventing and/or alleviating aberrant fibrotic tissue formations (e.g., scar formations). Specifically, compounds of the invention include agents that can interfere with multiple phases (multiple targets) of wound healing processes. These agents will be referred to as "multi-phase modulators" or "multi-target modulators." The "multi-phase modulators" or "multi-target modulators" may include multikinase inhibitors that can inhibit multiple kinases, as well as soluble guanylate cyclase (SGC) stimulators that can stimulate the activities of soluble guanylate cyclase.
[0010] In one aspect, embodiments of the invention relate to methods for preventing and/or modulating formation of a dermal fibrotic disorder. A method in accordance with embodiments of the invention includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The subject may be a mammal, particularly a human.
[0011] In accordance with embodiments of the invention, a multi-phase modulator may be a multiple-kinase ("multikinase") inhibitor or a soluble guanylate cyclase (SGC) stimulator (e.g., riociguat). As used herein, the term a "multikinase inhibitor" refers to a compound that can inhibit multiple kinases, particularly multiple receptor tyrosine kinases. A soluble guanylate cyclase (SGC) stimulator can stimulate the activity of an SGC, leading to the formation of cyclic GMP (cGMP), which is a second messenger in various signal transduction pathways. [0012] In accordance with embodiments of the invention, a multikinase inhibitor, for example, may include axitinib, nintedanib, sorafenib, sunitinib or lenvatinib, which can inhibit receptor tyrosine kinases, such as VEGFR receptors (VEGFR-1, VEGFR- 2, and/or VEGFR-3) and PDGF receptors (PDGFR1 and/or PDGFR2). In addition, compounds of the invention (e.g., axitinib, nintedanib, sorafenib, sunitinib, and lenvatinib) also have various degrees of inhibitory potencies against fibroblast growth factor receptors (FGFR).
[0013] In accordance with embodiments of the invention, the multikinase inhibitors may include, but are not limited to, axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and their stereoisomer, tautomer, prodrug, free base, analogs, metabolites, pharmaceutically acceptable salt, solvate or solvate of a salt thereof. These compounds have anti-multikinase activities, such as anti- VEGFR, anti-PDGFR, and/or anti-FGFR activities. As shown in this description, these multikinase inhibitors can inhibit exuberant tissue fibrosis or scar formation. They are effective in remedying undesired scar formation, presumably due to their abilities to inhibit multiple kinases, such as receptor tyrosine kinases that mediate signal transductions in the various phases of wound healing, thereby modulating the wound healing processes at multiple phases.
[0014] As used herein, a "pharmaceutically acceptable salt" refer to a compound that has been modified by adding an acid or base to make a salt thereof, wherein the compound may be a parent compound, or a prodrug, a derivative, a metabolite, or an analog of the parent compound.
[0015] In accordance with some embodiments of the invention, the multikinase inhibitor is axitinib. Axitinib is a tyrosine kinase inhibitor of VEGFR- 1, VEGFR-2 and VEGFR-3. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival. Axitinib also inhibits closely related receptor tyrosine kinases (RTKs), such as PDFGR-1, PDGFR-2, and KIT.
[0016] In accordance with some embodiments of the invention, the multikinase inhibitor is nintedanib. Nintedanib is tyrosine kinase inhibitor of various receptors, such as VEGFR, FGFR, PDGFR-a and PDGFR-β, and FGF. [0017] In accordance with some embodiments of the invention, the multikinase inhibitor is sorafenib. Sorafenib is a tyrosine kinase inhibitor of several receptors, such as VEGFR-2, VEGFR-3 and PDGFR2
[0018] In accordance with some embodiments of the invention, the multikinase inhibitor is sunitinib. Sunitinib is tyrosine kinase inhibitor of VEGFR and PDGFR.
[0019] In accordance with some embodiments of the invention, the multikinase inhibitor is lenvatinib. Lenvatinib is a tyrosine kinase receptor inhibitor of various receptors, such as VEGFR- 1, VEGFR-2, VEGFR-3, FGFR-1, FGFR-2, FGFR-3, FGFR-4, and PDGFR-a.
[0020] In accordance with some embodiments of the invention, the multi-phase modulator is an SGC stimulator, such as riociguat. Riociguat, a soluble guanylate cyclase stimulator, may have effects on proliferation, fibrosis and inflammation in wound healing.
[0021] In accordance with embodiments of the invention, an agent for controlling exuberant activities in various phases of wound healing may be used with other types of agents that can interfere with one or more phases involved in wound healing. These other agents may include anti-angiogenic agents, anti-inflammatory agents, or anti- vascular permeability agents. Preferred anti-angiogenic agents include, but are not limited to, tyrosine kinase inhibitors, in particular, those targeting multiple receptors, such as those described in further detail herein: angiostatic cortisenes; matrix metalloprotease inhibitors; integrin inhibitors; PDGF antagonists; anti-proliferatives; hypoxia inducible factor-I inhibitors; fibroblast growth factor inhibitors; epidermal growth factor inhibitors; tissue inhibitor of metalloproteinases inhibitors; insulin-like growth factor inhibitors; tumor necrosis factor inhibitors; antisense oligonucleotides; anti-VEGF antibody, VEGF trap, anti-VEGF and/or anti-PDGF compounds, and their stereoisomer, tautomer, prodrug, free base, analogs, metabolites, pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
[0022] In accordance with embodiments of the invention, the dermal fibrotic disorders include but not limited to acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, Peyronie's disease, dupuytren's contracture, or adhesive capsulitis. [0023] In accordance with embodiments of the invention, compounds/molecules of the present invention may be administered by oral, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingual, intramuscular, intradermal, subcutaneous, topical, intranasal, intraperitoneal, intrathoracic, intralesional, paralesional, intravenous, epidural, intrathecal, or intracerebroventricular routes, or by injection into the tissue and/or joints.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1 shows TGF-βΙ mRNA expression levels in wound sites treated with compounds of the invention relative to those in an untreated unwounded site on the dorsum of pigs.
[0025] FIG. 2 shows images of pig dermal tissues from histologic slides after hematoxylin and eosin staining. There was a decrease in neovascularization and fibrosis in drug treatment groups as compared to the untreated wound control. Panel (A) unwounded normal skin. Panel (B) untreated wound tissue, showing more neovascularization and fibrosis. Panel (C) axitinib treated wound, showing neovascularization and reduced fibrosis.
[0026] FIG. 3 shows results of nintedanib (labeled as AIV002) treatment of rabbit ear hypertrophic scar. Nintedanib treatment decreased neovascularization and dermal fibrosis. Panel (A) shows H&E staining (left: untreated; right: treated wound), wherein the untreated site has substantial neovascularization (left), relative to the treated site (right). Panel (B) shows Mason' s Trichrome staining (left: untreated; right treated wound).
DETAILED DESCRIPTION
[0027] Embodiments of the present invention relate to compositions (multi-phase modulators) and methods for preventing and/or modulating the formation of dermal fibrotic disorders. Dermal wound healing involves several phases: hemostasis, inflammation, proliferation, and tissue maturation. The overall process is induced and regulated by a complex array of factors, such as growth factors and cytokines. Effective approaches to the control of exuberant activities in would healing likely require controls and modulations in multiple phases. [0028] Factors involved in wound healing exert their functions by binding to their respective receptors to activate various signaling pathways. These receptors include tyrosine kinases. Therefore, receptor tyrosine kinase inhibitors (particularly multikinase inhibitors) can be used to regulate the exuberant wound healing processes. Embodiments of the invention are based on therapeutic utilities of compounds that possess a certain spectrum of pharmacologic effects to modulate exuberant activities in various phases of wound healing, thereby preventing and/or alleviating aberrant fibrotic tissue formations (e.g., scar formations).
[0029] Because various kinases are involved in different phases of the wound healing processes, compounds of the invention include multikinase inhibitors that can inhibit multiple kinases, thereby interfering with multiple kinase-mediated signaling pathways. By inhibiting multiple kinases, one can achieve overall effects that may not be achievable by inhibiting a single kinase. In other words, by inhibiting multiple kinases in multiple phases of the wound healing processes, one may be able to achieve therapeutically effective effects to have a meaningful control of the undesirable fibrosis.
[0030] Compounds of the invention, for example, may include axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, and regorafenib, which can potently inhibit receptor tyrosine kinases, such as VEGFR receptors (VEGFR-l, VEGFR-2, and/or VEGFR-3) and/or PDGF receptors (PDGFRl and/or PDGFR2). In addition, these compounds also have different extents of inhibitory potencies against fibroblast growth factor receptors (FGFR). Having the abilities to inhibit multiple receptor tyrosine kinases (e.g., VEGFR, PDGFR, and/or FGFR), these compounds can produce effective controls of undesirable fibrosis, such as in scar formation.
[0031] In addition to multikinase inhibitors, soluble guanylate cyclase (SGC) stimulators may also be used in embodiments of the invention. SGC stimulators may also interfere with multiple phases of wound healing. Thus, in accordance with some embodiments of the invention, a compound of the invention may be an SGC stimulator, such as riociguat.
[0032] As used herein, the term "dermal fibrotic disorder" refers to exuberant activities in various phases of wound healing that would result in aberrant fibrotic tissue formations (e.g., scar formations). [0033] As used herein, the term a "therapeutic effective amount" is an amount that would achieve the desired therapeutic effects. A therapeutic effective amount would depend on the patient conditions, routes of administration, administration regimes etc. One skilled in the art would be able to determine a therapeutic effective amount without inventive efforts.
[0034] The following describes some specific examples to illustrate embodiments of the invention. One skilled in the art would appreciate that these examples are for illustration only and other modifications and variations are possible without departing from the scope of the invention.
EXPERIMENT #1
[0035] Porcine skin resembles human skin in many aspects. Both species have a relatively thick epidermis, distinct rete pegs, dermal papillae, and dense elastic fibers in the dermis. Furthermore, unlike rodents and rabbits, porcine skin is adherent to the subcutaneous structures, similar to human skin. Because of these anatomical similarities and other parallelisms in wound healing, porcine models have emerged as important foundations for the study of pathophysiology and potential treatment paradigms for abnormal wound healing. It has also been observed in porcine full- thickness wound healing in Yucatan Minipigs that the spatial and temporal expressions of TGF-B1, PDGF and VEGF were similar to the patterns for the growth factors described above. Therefore, the full-thickness excision models in Yucatan minipigs are the models for human wound healing studies.
[0036] In this experiment, multiple full-thickness excision wounds were made to the dorsum of Yucatan minipigs, and the wound sites were allowed to re-epithelialized adequately. At four weeks post-wound, the wound sites had normal to pink vascularity and had pliability. Epidermal hyperplasia was observed, as expected for regenerative responses in the full-thickness wounds.
[0037] On Day 28 post-wound, a dose (e.g., 1%) of axitinib, nintedanib, riociguat, sorafenib, sunitinib, and/or lenvatinib was administered into the dermal tissue at or around the wound sites, once every two weeks on two occasions. One wound site was left untreated as the control for each pig. Please note that the particular parameters in this example are only for illustration. One skilled in the art would appreciate that the dosages, administration methods, treatment regimen, and the administration sites may be varied to achieve similar results.
[0038] On Day 59 post wound, the minipigs were sacrificed and dermal tissues were collected for qualitative and quantitative evaluation using hematoxylin and eosin, and Mason's Trichrome staining. Dermal fibroplasia was characterized by increased numbers of fibroblasts in the dermis suspended in variable amounts of collagen in wounds.
[0039] In addition, total mRNA was isolated from skin biopsies of the treated wound sites and the untreated unwounded sites of the pigs. The mRNA samples were used to prepare cDNA and analyzed via qRT-PCR. The TGF-βΙ expression levels were assessed using beta actin as a reference gene.
[0040] Transfomiing-growth-factor (ΤΟΡ)-β expression, following inflammatory responses, results in increased production of extracellular matrix (ECM) components, as well as mesenchymal cell proliferation, migration, and accumulation. Therefore, TGF-β has been found to induce fibrosis associated with chronic phases of inflammatory diseases. As shown in FIG. 1, compounds of the invention significantly reduced the expression levels of TGF-βΙ, suggesting that compounds of the invention can be used to control undesired fibrosis.
[0041] The histologic evaluation results, shown in Table 1, indicate that these compounds are effective in controlling the undesirable neovascular and fibrotic formation.
[0042] Among the various test compounds administered as two biweekly treatments, axitinib and nintedanib noticeably reduced neovascularization with a corresponding reduced dermal fibroplasia, as assessed by histopathologic examinations of the treated wounds relative to the untreated wound (Table. 1).
[0043] FIG. 2 shows exemplary hematoxylin and eosin stainings of pig dermal tissues from treated and untreated wound sites. Panel (A) show a staining from an unwounded skin as a control. Panel (B) shows a staining of a sample from a wounded site without treatment with any compound of the invention. It is evident that the wounded tissue has substantial neovascularization and fibrosis. Panel (C) shows a staining of a sample from a wounded site treated with axitinib. Axitinib treatment results in significantly reduced neovascularization and reduced fibrosis, as compared with the untreated wound (see Panel (B)). These results clearly show that compounds of the invention are effective in reducing neovascularization and fibrosis at the wounded sites. As a result, compounds of the invention may be used to reduce undesired fibrosis, such as scar formation.
Table 1. Qualitative assessments of dermal fibroplasia and neovascularization at wound sites after two doses, (minimal = 1, mild = 2, moderate = 3, marked = 4, and severe=5)
Figure imgf000010_0001
As shown in Table 2, compounds of the invention also resulted in reduction of TGF-βΙ mRNA expression levels at the treated wounds, as compared to the expression level in unwounded normal skin, suggesting that compounds of the invention can be used to control the exuberant fibrosis. Among these compounds, axitinib, nintedanib, riociguat, sorafenib, and sunitinib are the most effective.
Table 2. TGF-βΙ mRNA expression in Yucatan pig skin wound sites after treatments.
Figure imgf000010_0002
EXPERIMENT #2
[0045] In rabbits, wounds are created down to the bare cartilage on the ventral surface of the ear using a dermal biopsy punch. Because these wounds do not heal by contraction, epithelialization is delayed and a raised scar is created. By both appearance and histological analysis, these scars resemble human hypertrophic scars. In this established model, it was shown that reduced TGF- β expression results in reduced scarring, which is consistent with the current understanding of the pathogenesis of excessive scarring/dermal fibrosis. Furthermore, excessive angiogenesis and vascularization have been shown to result in pathological hypertrophic scar in this model. Thus, this rabbit model was also used to assess the compounds of the invention.
[0046] Eight wounds were created on the ventral surface of the ears of each of New
Zealand White rabbits using skin punch biopsies, and then the wounds were allowed to heal for approximately 2 weeks.
[0047] A dose (e.g., 1%) of axitinib, nintedanib, riociguat, sorafenib, sunitinib, and/or lenvatinib was administered into the dermal tissue, once every two weeks on two occasions. Again, the specific doses, treatment methods and schedules are for illustration only. One skilled in the art would appreciate that variations and modifications are possible to achieve similar results.
[0048] On Day 42 post wound, the rabbits were sacrificed and dermal tissues were collected for qualitative and quantitative evaluation using hematoxylin and eosin and Mason's Trichrome staining. In addition, TGF-βΙ mRNA expression levels were measured using qRT-PCR.
[0049] Histologic slides for hematoxylin and eosin stainings were prepared from the wound sites. Tissues were evaluated qualitatively for inflammation, neovascularization, granulation tissue, degrees of re-epithelialization, and degrees of scarring (avascular collagen).
[0050] As compared with untreated wound and the vehicle-treated wound, the wounds treated with nintedanib had much less neovascularization and less scar tissues. As compared with the vehicle-treated wound, the mean TGFbl mRNA level was lower after intradermal treatment with nintedanib.
[0051] FIG. 3 shows results of nintedanib (labeled as AIV002) treatment of rabbit ear hypertrophic scar. Nintedanib treatment decreased neovascularization and dermal fibrosis. Panel (A) shows H&E staining (left: untreated; right: treated wound), wherein the untreated site has substantial neovascularization (left), relative to the treated site (right). Panel (B) shows Mason' s Trichrome staining (left: untreated; right treated wound).
[0052] In addition to nintedanib, other compounds of the invention also have similar effects. For example, As compared with the untreated wound and the vehicle-treated wound, the wounds treated with axitinib had less neovascularization, less fibrosis, and less scar tissues. As compared with the vehicle-treated wound, the mean TGFbl mRNA level was lower after intradermal treatment with axitinib.
[0053] As compared with untreated wound and the vehicle-treated wound, the wounds treated with riociguat had slightly decreased neovascularization and fibrosis.
[0054] As compared with untreated wound and the vehicle-treated wound, the wounds treated with sorafenib had slightly increased neovascularization, and similar or decreased fibrosis. As compared with vehicle-treated wound, the mean TGFbl mRNA level was lower after intradermal treatment with sorafenib.
[0055] As compared with untreated wound and the vehicle-treated wound, the wounds treated with sunitinib had more neovascularization, and similar fibrosis. As compared with the vehicle-treated wound, the mean TGFbl mRNA level was lower after intradermal treatment with sunitinib.
[0056] As compared with untreated wound and the vehicle-treated wound, intradermal treatment with lenvatinib had similar neovascularization, fibrosis, and re- epithelialization. As compared with the vehicle-treated wound, the mean TGFbl mRNA level was lower after intradermal treatment with lenvatinib.
Table 3. TGF-βΙ mRNA expression in rabbit ear wound sites after intradermal treatments.
Figure imgf000012_0001
5
Treated (each
or 0.87 ± 0.28 0.73 ± 0.13 1.14 ± 0.14 0.87 ± 0.13 0.76 ± 0.23 0.66 ± 0.25 drug)
6
1
Vehicle (each
or 1.09 1.03 ± 0.19 1.01 ± 0.22 0.87 ± 0.20 1.26 ± 0.79 0.73 ± 0.09 drug)
2
[0057] While the invention has been described with respect to a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that other embodiments can be devised which do not depart from the scope of the invention as disclosed herein. Accordingly, the scope of the invention should be limited only by the attached claims.

Claims

CLAIMS What is claimed is:
1. A method for preventing and/or modulating formation of a dermal fibrotic disorder, comprising:
administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof.
2. The method according to claim 1, wherein the multi-phase modulator is a multi-kinase inhibitor or a soluble guanylate cyclase stimulator.
3. The method according to claim 1, wherein the mutli-phase modulator is a multi-kinase inhibitor.
4. The method according to claim 3, wherein the multi-kinase inhibitor is selected from the group consisting of axitinib, nintedanib, riociguat, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and a combination thereof
5. The method according to claim 1, wherein the multi-phase modulator is a soluble guanylate cyclase stimulator.
6. The method according to claim 5, wherein the soluble guanylate cyclase stimulator is riociguat.
7. The method according to any one of claims 1-6, wherein said dermal fibrotic disorder is acne scar, skin scar, wrinkle, cellulite and dermal neoplastic fibrosis, scarring alopecia, vasculopathy, vasculitis, exuberant burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, Peyronie' s disease, dupuytren's contracture, or adhesive capsulitis.
8. The method according to any one of claims 1-7, wherein the subject is a human.
9. The method according to any one of claims 1-8, wherein the administering is by oral, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingual, intramuscular, subcutaneous, topical, intranasal, intraperitoneal, intrathoracic, intravenous, epidural, intrathecal, or intracerebroventricular route, or by injection into joint.
10. A composition for use in preventing and/or modulating formation of a dermal fibrotic disorder, comprising: a multi-phase modulator selected from the group consisting of a multikinase inhibitor and a soluble guanylate stimulator.
11. The composition according to claim 10, wherein the multikinase inhibitor is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and a combination thereof.
12. The composition according to claim 10, wherein the soluble guanylate cyclase stimulator is riociguat.
13. The composition according to any one of claims 10-12, wherein the dermal fibrotic disorder is acne scar, skin scar, wrinkle, cellulite and dermal neoplastic fibrosis, scarring alopecia, vasculopathy, vasculitis, exuberant burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, Peyronie's disease, dupuytren's contracture, or adhesive capsulitis.
14. The composition according to any one of claims 10-13, wherein the composition is formulated for administering by oral, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingual, intramuscular, subcutaneous, topical, intranasal, intraperitoneal, intrathoracic, intravenous, epidural, intrathecal, or intracerebroventricular route, or by injection into joint.
PCT/US2016/055865 2015-10-07 2016-10-07 Compositions and methods of treating skin fibrotic disorders Ceased WO2017062694A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US15/767,137 US10736885B2 (en) 2015-10-07 2016-10-07 Compositions and methods of treating dermal fibrotic disorders
CA3001489A CA3001489C (en) 2015-10-07 2016-10-07 Compositions and methods of treating skin fibrotic disorders
EP16854374.2A EP3359258A4 (en) 2015-10-07 2016-10-07 COMPOSITIONS AND METHODS FOR TREATING FIBROUS SKIN DISORDERS
AU2016335675A AU2016335675B2 (en) 2015-10-07 2016-10-07 Compositions and methods of treating skin fibrotic disorders
KR1020187012515A KR102317700B1 (en) 2015-10-07 2016-10-07 Compositions and methods for treating skin fibrotic disorders
JP2018538059A JP7153331B2 (en) 2015-10-07 2016-10-07 Compositions for treating skin fibrotic disorders
CN201680071285.5A CN108367165B (en) 2015-10-07 2016-10-07 Compositions and methods for treating skin fibrotic disorders
US16/920,278 US20200330446A1 (en) 2015-10-07 2020-07-02 Compositions and methods of treating skin fibrotic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238309P 2015-10-07 2015-10-07
US62/238,309 2015-10-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/767,137 A-371-Of-International US10736885B2 (en) 2015-10-07 2016-10-07 Compositions and methods of treating dermal fibrotic disorders
US16/920,278 Continuation US20200330446A1 (en) 2015-10-07 2020-07-02 Compositions and methods of treating skin fibrotic disorders

Publications (1)

Publication Number Publication Date
WO2017062694A1 true WO2017062694A1 (en) 2017-04-13

Family

ID=58488503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/055865 Ceased WO2017062694A1 (en) 2015-10-07 2016-10-07 Compositions and methods of treating skin fibrotic disorders

Country Status (8)

Country Link
US (2) US10736885B2 (en)
EP (1) EP3359258A4 (en)
JP (1) JP7153331B2 (en)
KR (1) KR102317700B1 (en)
CN (1) CN108367165B (en)
AU (1) AU2016335675B2 (en)
CA (1) CA3001489C (en)
WO (1) WO2017062694A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148653A1 (en) * 2017-02-12 2018-08-16 Aiviva Holding Limited Multikinase inhibitors of vegf and tgf beta and uses thereof
WO2018218116A1 (en) * 2017-05-26 2018-11-29 Scott Whitcup A topical composition for treating rosacea and a method for treating rosacea with the same
CN109996814A (en) * 2017-05-01 2019-07-09 艾葳控股有限公司 Multi-kinase inhibitor and the purposes in eye fibrosis
KR20200039752A (en) * 2017-08-12 2020-04-16 아이비바 바이오파마, 인크. Multikinase inhibitors, and uses in reproductive and digestive tract fibrosis
CN111655339A (en) * 2017-12-30 2020-09-11 艾葳生物科技有限公司 Multikinase inhibitors and their use in benign prostatic hyperplasia and urinary tract diseases
CN111741749A (en) * 2018-01-19 2020-10-02 艾葳生物科技有限公司 Suspension compositions of multitarget inhibitors
TWI720582B (en) * 2018-08-15 2021-03-01 美商艾葳生物科技有限公司 Multi-kinase inhibitors of vegf and tgf beta and uses thereof
WO2022234593A1 (en) * 2021-05-02 2022-11-10 Zenvision Pharma Llp Sublingual compositions comprising nintedanib or salt thereof
WO2025221152A1 (en) * 2024-04-16 2025-10-23 Aft Pharmaceuticals Limited Treatment for cutaneous scars
WO2026022657A1 (en) * 2024-07-21 2026-01-29 Cology Biosciences Private Limited Novel sublingual compositions for the treatment of fibrotic diseases and hypertensive diseases

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520867A (en) * 2020-04-08 2023-05-22 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー Treatment Strategies to Address Post-Injury Facial Contractures
CN113679722A (en) * 2021-09-27 2021-11-23 张国华 Compositions and methods for treating neovascularized skin disorders
WO2025007166A1 (en) * 2023-06-29 2025-01-02 University Of Cape Town Bcr-abl inhibitors for use in treating keloid disease
CN118416065A (en) * 2024-01-18 2024-08-02 中国医学科学院整形外科医院 Application of crizotinib in the preparation of drugs or devices for preventing or treating scars

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060079A1 (en) 2009-11-10 2011-05-19 The Trustees Of Columbia University In The City Of New York Compositions and methods for wound treatment
US20130210733A1 (en) * 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
PE20060777A1 (en) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
AU2009244267A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by miRNA
US20110129463A1 (en) * 2009-11-27 2011-06-02 Proteologics, Ltd. Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
CN103038232B (en) * 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 Independent and combined with PDE5 inhibitor sGC stimulant, sGC activator are used for the treatment of the purposes of systemic sclerosis (SSc)
EP2595628A1 (en) * 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2877710A1 (en) * 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
CA2877715A1 (en) * 2012-06-25 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing axitinib
WO2014028595A1 (en) * 2012-08-14 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated ponatinib
JP6386467B2 (en) * 2012-11-16 2018-09-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Novel heterocyclic derivatives as modulators of kinase activity
US9642851B2 (en) * 2012-12-06 2017-05-09 Kbp Biosciences Co., Ltd. Indolinone derivative as tyrosine kinase inhibitor
WO2015005985A1 (en) * 2013-07-11 2015-01-15 Precision Dermatology, Inc. Topical treatment of localized scleroderma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060079A1 (en) 2009-11-10 2011-05-19 The Trustees Of Columbia University In The City Of New York Compositions and methods for wound treatment
US20130210733A1 (en) * 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN MEDICINES AGENCY: "Public Summary of Opinion on Orphan Designation Riociguat for the Treatment of Systemic Sclerosis", SCIENCE MEDICINES HEALTH, 27 August 2014 (2014-08-27), XP055372486 *
GESCHKA ET AL.: "Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats", PLOS ONE, vol. 6, no. 7, 18 July 2011 (2011-07-18), pages e21853, XP055372489 *
See also references of EP3359258A4

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
US12138252B2 (en) 2017-02-12 2024-11-12 Aiviva Biopharma, Inc. Multikinase inhibitors of VEGF and TGF beta and uses thereof
JP2020507583A (en) * 2017-02-12 2020-03-12 アイビバ バイオファーマ インコーポレイテッド Multikinase inhibitors of VEGF and TGFbeta and uses thereof
WO2018148653A1 (en) * 2017-02-12 2018-08-16 Aiviva Holding Limited Multikinase inhibitors of vegf and tgf beta and uses thereof
CN109996814B (en) * 2017-05-01 2023-08-11 艾葳生物科技有限公司 Multi-kinase inhibitors and their use in ocular fibrosis
JP2019524880A (en) * 2017-05-01 2019-09-05 アイビバ バイオファーマ インコーポレイテッド Multikinase inhibitor
EP3619232B1 (en) 2017-05-01 2023-06-07 AiViva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
CN109996814A (en) * 2017-05-01 2019-07-09 艾葳控股有限公司 Multi-kinase inhibitor and the purposes in eye fibrosis
EP3619232A4 (en) * 2017-05-01 2021-01-13 AiViva Biopharma, Inc. MULTIKINASE INHIBITORS AND THEIR USES IN OCULAR FIBROSIS
WO2018218116A1 (en) * 2017-05-26 2018-11-29 Scott Whitcup A topical composition for treating rosacea and a method for treating rosacea with the same
US11179388B2 (en) 2017-05-26 2021-11-23 Ads Therapeutics Llc Topical composition for treating rosacea and a method for treating rosacea with the same
CN111278463A (en) * 2017-08-12 2020-06-12 艾葳生物科技有限公司 Multikinase inhibitors and their use in reproductive and digestive tract fibrosis
JP2020535216A (en) * 2017-08-12 2020-12-03 アイビバ バイオファーマ インコーポレイテッド Multi-target kinase inhibitor and use in genital and gastrointestinal fibrosis.
CN116459253A (en) * 2017-08-12 2023-07-21 艾葳生物科技有限公司 Multi-kinase inhibitors and their use in genital and digestive tract fibrosis
EP3664847A1 (en) * 2017-08-12 2020-06-17 AiViva Biopharma, Inc. Multikinase inhibitors and uses in reproductive and digestive tract fibrosis
KR102448705B1 (en) * 2017-08-12 2022-09-28 아이비바 바이오파마, 인크. Multikinase Inhibitors and Uses in Reproductive and Gastrointestinal Fibrosis
JP2022078298A (en) * 2017-08-12 2022-05-24 アイビバ バイオファーマ インコーポレイテッド Multi-target kinase inhibitor and use in genital and gastrointestinal fibrosis.
KR20200039752A (en) * 2017-08-12 2020-04-16 아이비바 바이오파마, 인크. Multikinase inhibitors, and uses in reproductive and digestive tract fibrosis
JP7174444B2 (en) 2017-12-30 2022-11-17 アイビバ バイオファーマ インコーポレイテッド Multikinase inhibitors and use in benign prostatic hyperplasia and urinary tract disease
US11376252B2 (en) 2017-12-30 2022-07-05 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in prostatic hyperplasia and urinary track diseases
CN111655339A (en) * 2017-12-30 2020-09-11 艾葳生物科技有限公司 Multikinase inhibitors and their use in benign prostatic hyperplasia and urinary tract diseases
EP3731930A4 (en) * 2017-12-30 2021-10-20 AiViva Biopharma, Inc. MULTIKINASE INHIBITORS AND THEIR USES IN PROSTATE HYPERPLASIA AND URINARY TRACT DISEASES
CN111655339B (en) * 2017-12-30 2023-06-20 艾葳生物科技有限公司 Multikinase inhibitors and their use in benign prostatic hyperplasia and urinary tract disorders
JP2021509405A (en) * 2017-12-30 2021-03-25 アイビバ バイオファーマ インコーポレイテッド Multikinase inhibitors and uses in benign prostatic hyperplasia and urinary tract diseases
JP2023099169A (en) * 2018-01-19 2023-07-11 アイビバ バイオファーマ インコーポレイテッド Pharmaceuticals of multi-target inhibitors
JP2021511323A (en) * 2018-01-19 2021-05-06 アイビバ バイオファーマ インコーポレイテッド Suspension composition of multi-target inhibitor
CN111741749A (en) * 2018-01-19 2020-10-02 艾葳生物科技有限公司 Suspension compositions of multitarget inhibitors
KR20200113221A (en) * 2018-01-19 2020-10-06 아이비바 바이오파마, 인크. Suspension composition of multiple target inhibitors
KR102474404B1 (en) * 2018-01-19 2022-12-06 아이비바 바이오파마, 인크. Suspension compositions of multi-target inhibitors
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
CN112839652A (en) * 2018-08-15 2021-05-25 艾葳生物科技有限公司 Multikinase inhibitors of VEGF and TGFβ and their uses
EP3836927A4 (en) * 2018-08-15 2022-05-11 AiViva Biopharma, Inc. VEGF AND TGF-BETA MULTIKINASE INHIBITORS AND USES THEREOF
TWI720582B (en) * 2018-08-15 2021-03-01 美商艾葳生物科技有限公司 Multi-kinase inhibitors of vegf and tgf beta and uses thereof
JP2021534153A (en) * 2018-08-15 2021-12-09 アイビバ バイオファーマ インコーポレイテッド VEGF and TGF Beta Multikinase Inhibitors and Their Use
US12502391B2 (en) 2018-08-15 2025-12-23 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
WO2022234593A1 (en) * 2021-05-02 2022-11-10 Zenvision Pharma Llp Sublingual compositions comprising nintedanib or salt thereof
WO2025221152A1 (en) * 2024-04-16 2025-10-23 Aft Pharmaceuticals Limited Treatment for cutaneous scars
WO2026022657A1 (en) * 2024-07-21 2026-01-29 Cology Biosciences Private Limited Novel sublingual compositions for the treatment of fibrotic diseases and hypertensive diseases

Also Published As

Publication number Publication date
KR102317700B1 (en) 2021-10-26
US20200330446A1 (en) 2020-10-22
AU2016335675A1 (en) 2018-05-24
EP3359258A1 (en) 2018-08-15
CA3001489A1 (en) 2017-04-13
EP3359258A4 (en) 2019-08-21
CA3001489C (en) 2024-01-16
JP7153331B2 (en) 2022-10-14
AU2016335675B2 (en) 2022-04-28
CN108367165A (en) 2018-08-03
CN108367165B (en) 2022-03-04
JP2018534356A (en) 2018-11-22
US10736885B2 (en) 2020-08-11
US20190070160A1 (en) 2019-03-07
KR20180064461A (en) 2018-06-14

Similar Documents

Publication Publication Date Title
CA3001489C (en) Compositions and methods of treating skin fibrotic disorders
Occleston et al. New therapeutics for the prevention and reduction of scarring
Bignold et al. Effects of cytokine signaling inhibition on inflammation-driven tissue remodeling
Wang et al. Opioids and opioid receptors orchestrate wound repair
Zhou et al. Luteolin relieves lung cancer-induced bone pain by inhibiting NLRP3 inflammasomes and glial activation in the spinal dorsal horn in mice
Cheng et al. In vivo inhibition of hypertrophic scars by implantable ginsenoside-Rg3-loaded electrospun fibrous membranes
Zheng et al. The effect of topical ramipril and losartan cream in inhibiting scar formation
ES2949627T3 (en) Axitinib, nintedanib or lenvatinib for the treatment of rosacea and atopic dermatitis
Ozkan et al. The effect of bevacizumab and 5-Fluorouracil combination on epidural fibrosis in a rat laminectomy model.
Jia et al. Mechanism and application of β‐adrenoceptor blockers in soft tissue wound healing
Xu et al. The role and mechanism of Schwann cells in the repair of peripheral nerve injury
Prasad et al. Effects of the adenosine A2A receptor antagonist KW6002 on the dopaminergic system, motor performance, and neuroinflammation in a rat model of Parkinson's disease
Zhang et al. IL‐17A‐neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the CXCL5/CXCR2 axis
US10758559B1 (en) Targeting cathepsin K to facilitate wound healing
Silveira et al. Effects of unfocused extracorporeal shock wave therapy on healing of wounds of the distal portion of the forelimb in horses
CN105251008B (en) Application of MicroRNA-155 antagonist in preparation of medicine for treating scleroderma
Mony et al. An Updated Review of Hypertrophic Scarring. Cells 2023, 12, 678
Sato et al. Defect of Dectin-1-mediated signaling leads to promoted burn wound healing through attenuated oxidative stress and inflammatory responses
Xu et al. Ultrasound therapy of injury site modulates gene and protein expressions in the dorsal root ganglion in a sciatic nerve crush injury rat model
Lali et al. Advances in biopharmaceutical agents and growth factors for wound healing and scarring
Gao et al. Sgp130Fc regulates IL-6/JAK2/STAT3 trans-signaling pathway in rat vocal fold fibroblast activation
Chen et al. Healing mechanism of PSO on deep second-degree burn wounds in a porcine model
Zhang et al. Radiofrequency Therapy Attenuates Hypertrophic Scar Formation in Rabbit Ears by Modulating the TGF-β1/Smad3 Signaling Pathway
Gross et al. Mediators of inflammatory and ischemic renal damage: the role of neoangiogenesis
Lit et al. Insights into the unique roles of dermal white adipose tissue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16854374

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2018538059

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 3001489

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187012515

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016854374

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016335675

Country of ref document: AU

Date of ref document: 20161007

Kind code of ref document: A